NewburgerJWTakahashiMGerberMA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733.
3.
KatoHSugimuraTAkagiT. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-1385.
4.
MutaHIshiiMYashiroMUeharaRNakamuraY. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012;129:e291-e297.
5.
GordonJBKahnAMBurnsJC. When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood. J Am Coll Cardiol. 2009;54:1911-1920.
6.
BerardRWhittemoreBScuccimarriR. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J. 2012;10(1):10.
7.
TaddioAPellegrinMCCentenariCFilippeschiIPVenturaAMaggioreG. Acute febrile cholestatic jaundice in children: keep in mind Kawasaki disease. J Pediatr Gastroenterol Nutr. 2012;55:380-383.
8.
MinichLLSleeperLAAtzAM. Delayed diagnosis of Kawasaki disease: what are the risk factors?Pediatrics. 2007;120:e1434-e1440.
9.
BallowM. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122-132.
10.
KaarthigeyanKBurliVV. Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency. J Pediatr Neurosci. 2011;6:160-161.
